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Abstract
Background: We previously identified that Ran protein, a member of the Ras GTPase family, is highly expressed in
high grade and high stage serous epithelial ovarian cancers, and that its overexpression is associated with a poor
prognosis. Ran is known to contribute to both nucleocytoplasmic transport and cell cycle progression, but its role
in ovarian cancer is not well defined.
Results: Using a lentivirus-based tetracycline-inducible shRNA approach, we show that downregulation of Ran
expression in aggressive ovarian cancer cell lines affects cellular proliferation by inducing a caspase-3 associated
apoptosis. Using a xenograft tumor assay, we demonstrate that depletion of Ran results in decreased
tumorigenesis, and eventual tumor formation is associated with tumor cells that express Ran protein.
Conclusion: Our results suggest a role for Ran in ovarian cancer cell survival and tumorigenicity and suggest that
this critical GTPase may be suitable as a therapeutic target.
Background
Ovarian cancer is the leading cause of death from gyne-
cological cancer in western countries [1,2]. Being largely
asymptomatic, more than 70% of patients are diagnosed
with advanced stage disease. Despite various modifica-
tions in ovarian cancer therapy, there has been very lit-
tle progress in overall patient survival for the past 30
years and screening programs to detect early disease
have not been successful to date [3]. Approximately 90%
of ovarian cancers are of epithelial origin (EOC) and
these tumors can be classified into different histopathol-
ogies, of which the serous histotype is the most com-
mon [4]. Low malignant potential serous tumors have a
five year survival rate of 90-95%, whereas the survival
rate for invasive serous cancers drops dramatically to
35-40% [3].
Using a molecular profiling analysis, we previously
identified different genes that can distinguish between
low malignant potential tumors and invasive EOC [5].
Among interesting candidates, we studied the expression
of the Ras-related nuclear protein Ran [5] using an
immunohistochemistry approach on an EOC serous tis-
sue microarray. Ran overexpression was associated with
higher tumor grade and advanced stage disease. More-
over, Ran was the most significant marker able to pre-
dict patient survival with the highest combination of
sensitivity and specificity [6].
The Ran protein is a small GTPase of the Ras super-
family known to play different roles in normal cell phy-
siology. One of its major functions is to regulate the
nucleocytoplasmic transport of molecules through the
nuclear pore complex [7,8]. It has been proposed that
the unusual localization of oncogenes and/or tumor
suppressor proteins can be affected by Ran signaling in
different types of cancer [9]. Ran is also involved in cell
cycle progression through the regulation of mitotic spin-
dle formation [10]. Deregulation of this process may
lead to genomic instability, which is common in EOC.
Overexpression of Ran GTPase has also been observed
in various other malignancies when compared to their
normal tissue, including stomach, colon, pancreas, lung
and kidney cancer [11-13]. These observations indicate
that the deregulation of Ran expression may be an
important event in cell transformation or cancer pro-
gression [11].
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ovarian tumorigenesis, we investigated the effects of Ran
depletion in two aggressive EOC cell lines. Here, we
show that loss of Ran expression leads to cell death by a
caspase-3 associated apoptosis in vitro. Downregulation
of Ran in vivo was also associated with tumor regression
in SCID mice. This study demonstrates that the expres-
sion of Ran is important for EOC cell survival and sug-
gests that Ran may be a suitable therapeutic target for
the treatment of ovarian cancers.
Results
Ran expression in transduced cells
We have previously shown that Ran GTPase is overex-
pressed in invasive serous EOC as compared to low
malignant potential serous tumors [6]. To better under-
stand the role of Ran in ovarian tumorigenesis, we
downregulated its expression using a lentivirus-based
inducible short-hairpin RNA (shRNA) strategy in two
aggressive EOC cell lines derived in our laboratory (Fig-
ure 1) [14,15]. TOV112D is derived from a high grade
endometrioid tumor and has been extensively character-
ized [15]. TOV1946 originates from a high grade serous
carcinoma, which is the most common EOC histotype.
Both cell lines harbor p53 mutations, the most common
genetic lesion associated with high grade serous cancers.
Transfection of pcDNA6/TR generated clonal derivates
of these cell lines expressing the tetracycline repressor
( T e t R ) .T h i sa l l o w st h ei n ducible expression of the
shRNA when tetracycline is added to the media, thus
Figure 1 Ran expression in parental cell lines, mixed populations and clones. Comparison of Ran mRNA levels by Q-PCR in TOV112D TetR
(a) and TOV1946 TetR (b) parental cell lines, shRNA Ran or LacZ mixed populations and clones. Levels were normalized to parental cell line
without induction. Values represent the mean ± SD of two separate experiments each performed in duplicate. Western blot analysis of TOV112D
TetR (c) and TOV1946 TetR (d) parental cell lines, mixed populations and clones shRNA Ran or LacZ without and after three days of induction.
ß-actin was used as loading control. P: Parental cell line, M.P.: Mixed population, #1, #2 and #3: independent clones. Mann-Whitney test indicates
a significant difference with a p-value < 0.05 (*).
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Page 2 of 11preventing basal target gene knockdown. After transduc-
tion of the pLenti-X1 Puro DEST vector containing the
shRNA sequence specific to Ran or LacZ (as a control)
in cells, we generated mixed populations and different
independent clones of TOV112D TetR and TOV1946
TetR expressing shRNA Ran or LacZ. Q-PCR (Figure
1A and 1B), as well as immunoblot (Figure 1C and 1D)
assays, showed decreased Ran expression in both mixed
populations and clones expressing shRNA specific to
Ran after induction. Despite some variation seen at
mRNA and protein level in Ran expression after induc-
tion of the control shRNA LacZ (Figure 1), these minor
modulations seem to be related to clonal effects and are
not affecting the phenotype of the clones.
Effects of Ran downregulation on cellular proliferation
We measured cellular proliferation of TOV112D TetR
and TOV1946 TetR transduced with shRNA Ran in
order to examine if cellular growth was affected by the
loss of Ran. Cells expressing shRNA Ran or LacZ were
induced with 1 μg/mL tetracycline three days prior to
being seeded. We noted a significant decrease in cellular
proliferation in both the mixed population and the
clones with reduced Ran expression in comparison to
their non-induced counterpart. We also noted that the
reduction in cell proliferation may correlate with Ran
expression levels. Tetracycline induction of clone
shRNA Ran #3/TOV1946 TetR resulted in a partial
reduction of Ran protein levels and the effect of this
partial reduction on cell proliferation was modest when
compared to clones 1 and 2, where Ran inhibition was
stronger (Figure 2A and 2B). Induction of the shRNA
LacZ did not affect cell proliferation (Additional file 1).
Loss of Ran expression triggers apoptosis in EOC cells
After induction of shRNA expression, cells depleted for
Ran were rounder than observed with the parental cell
line and tended to detach from the culture surface, a
morphology characteristic of apoptotic cells (Figure 2C
and 2D). Moreover, cell numbers actually decreased
during shRNA Ran induction (Figure 2A and 2B). In
order to determine if these cells were dying by apopto-
sis, we used propidium iodide (PI) to analyze the DNA
content of the cells induced with tetracycline for
Figure 2 Effect of Ran depletion on proliferation. Growth curves for TOV112D TetR (a) and TOV1946 TetR (b) parental cell lines, mixed
populations and clones expressing shRNA Ran. Cells were induced with tetracycline three days prior to day 0. Cells were trypsinized and
counted every 24h for five days. Values represent mean ± SD of duplicate wells from three independent experiments. Cellular morphology of
TOV112D TetR (c) and TOV1946 TetR (d) on day 5 of the growth curve. Loss of Ran GTPase expression results in cell number reduction and
round shaped cells. All pictures were taken at 100× magnification. P: Parental cell line, M.P.: Mixed population, #1, #2 and #3: independent
clones. Mann-Whitney test indicates a significant difference relative to the non-induced parental cell line with a p-value < 0.05 (*). There was no
significant difference between the different non-induced cells.
Barrès et al. Molecular Cancer 2010, 9:272
http://www.molecular-cancer.com/content/9/1/272
Page 3 of 11different time periods and examined the sub-G1 fraction.
Cells in sub-G1 phase represent hypodiploid DNA typi-
cally associated with late apoptosis or necrosis [16].
Since the different clones expressing shRNA Ran all
behaved similarly, we subsequently looked at clones
where Ran knockdown was most evident in addition to
the mixed population. We observed a rapid sub-G1
accumulation after tetracycline induction in TOV112D
TetR shRNA Ran, and a similar sub-G1 phase appeared,
although more slowly, in TOV1946 TetR cells (Figure
3A and 3B). The proportion of sub-G1 fraction was
comparable in mixed populations and clones, but was
greater in the TOV112D TetR shRNA Ran compared to
the TOV1946 TetR shRNA Ran. No increase in the sub-
G1 fraction was observed at any time in the shRNA
LacZ controls (Figure 3A and 3B).
Sub-G1 DNA is generated by late apoptotic or necro-
tic cells. To confirm that cells had undergone apoptosis
and not necrosis following Ran depletion, we examined
caspase-3 activation, a key downstream step in the
apoptosis pathway [17]. After three days of induction
with tetracycline, caspase-3 was cleaved in both mixed
populations and clones expressing shRNA Ran in both
cell lines (Figure 3C and 3D). We assayed caspase-3
cleavage under different induction time periods, and
observed by western blotting that cleavage appeared
after 60 h in both cell lines, and a slight band was
apparent after 48 h induction in the shRNA Ran clones
from both cell lines (Figure 3E and 3F). Therefore, the
caspase-3 cleavage appears before the sub-G1 cells
population in both cell lines. No cleavage of the cas-
pase-3 was observed in the controls.
Mitochondria play a key role in the regulation of
apoptosis with depolarization of the outer mitochondrial
membrane being a point of no return in the apoptotic
cascade [18,19]. Using tetramethylrhodamine ethylester
(TMRE), we assayed outer membrane depolarization
and noted that, in both cell lines, a decrease Ran expres-
sion resulted in a reduced outer membrane potential,
observable after 48-60 h (Figure 3G and 3H). This mem-
brane potential reduction was not seen in control
shRNA LacZ. Thus, apoptosis was triggered between
48-60 h after Ran depletion in both cell lines, indicating
that decrease of Ran expression promotes caspase-3
associated apoptosis.
Knockdown of Ran causes regression of tumors in vivo
We showed that EOC cells are dependant on Ran
expression to survive in vitro. In order to understand if
Ran is also important for tumor cell survival in vivo,w e
used a xenograft-based model of tumor growth in SCID
mice. As we have previously shown that TOV112D cells
are highly aggressive when tested in a xenograft model
[15], we chose to focus on this cell line for in vivo
experiments. The short time course of tumor formation
also minimized confounding effects related to the possi-
ble loss of shRNA expression in mice. After nine days,
when tumors reached an average size of 150 mm
3,m i c e
were given food supplemented with doxycycline in order
to induce shRNA expression in tumor cells. Loss of Ran
expression, in tumors expressing the mixed population
shRNA Ran, resulted in a modest delay in tumor
growth, where the difference in tumor size was statisti-
cally significant at day 19 (Figure 4A). In mice injected
with cells containing an inducible clone of shRNA Ran,
tumor growth was delayed for several days after induc-
tion of shRNA expression and tumor sizes were statisti-
cally different at every measurement time point after
day 15. Mice were sacrificed when tumors reached
about 2300 mm
3. All mice of the clone shRNA Ran
non-induced group were sacrificed by day 27, while in
the group where shRNA Ran was expressed, the last
mouse was sacrificed at day 54. No major differences
were observed in tumor volume between the induced
and non-induced group of mice expressing shRNA LacZ
in mixed populations or clones (Additional file 2). At
day 0, 3 and 6 after shRNA induction and at the day of
sacrifice, one mouse of each group was sacrificed to
analyze tumor histology. The different stainings were
performed on contiguous sections of the tissue microar-
ray and the average and most representative staining
were chosen for presentation. Analysis of Ran protein
expression by immunohistochemistry demonstrated a
reduced cytoplasmic expression in shRNA Ran mice
after six days of induction with doxycycline-supplemen-
ted food (Figure 4B). In these tumors, we noted the pre-
sence of cleaved caspase-3 in the nucleus, which was
absent in the controls. Ki67 staining showed that
nuclear localization of the protein was impaired when
Ran was downregulated (Figure 4B). Tumor analysis of
the mice from the shRNA Ran/doxycycline-supplemen-
t e df o o dg r o u pa tt h ed a yo fs a c r i f i c es h o w e dt h a tR a n
levels were comparable to controls (Figure 4B). Despite
t h ef a c tt h a tt u m o r sf r o ms h R N AL a c Zm i x e dp o p u l a -
tion grew faster than the clone, which is due to a clonal
effect, no other differences were seen in shRNA LacZ
with or without induction (Additional file 3). These
results not only suggest that reduced expression of Ran
is associated with tumor growth inhibition, but also sug-
gest a strong selection pressure for Ran expression in
those tumors that eventually develop in mice.
Discussion
We previously demonstrated that Ran, a small GTP
binding protein belonging to the Ras super-family, is
overexpressed in invasive versus low malignant potential
EOCs. Furthermore, the level of Ran overexpression cor-
relates with a poorer prognosis among patients with
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Page 4 of 11Figure 3 Loss of Ran expression results in a caspase-3 associated apoptosis in ovarian cancer cell lines. TOV112D TetR (a) and TOV1946
TetR (b) parental cell lines, mixed populations and clones expressing shRNA LacZ and Ran were induced with tetracycline for the indicated
times and then fixed in 70% ethanol. Cells were treated with propidium iodide and sub-G1 peaks were quantified by flow cytometry. Values
represent the mean ± SD of three independent experiments. Western blot analysis showing caspase-3 cleavage in cell depleted in Ran
expression after 3 days of induction in TOV112D TetR (c) and TOV1946 TetR (d). Kinetic of caspase-3 cleavage by western blot analysis in
TOV112D TetR (e) and TOV1946 TetR (f) parental cell lines, mixed populations and clones expressing shRNA LacZ and Ran. TOV112D TetR (g) and
TOV1946 TetR (h) parental cell lines, mixed populations and clones expressing shRNA LacZ and Ran were induced with tetracycline for the
indicated time and then treated with TMRE for 20 minutes. ΔΨm reduction was measured by flow cytometry. Values represent the mean ± SD
of three independent experiments. P: Parental cell line, M.P.: Mixed population, #1, #2 and #3: independent clones. Mann-Whitney test indicates a
significant difference relative to the non-induced sample with a p-value < 0.05 (*).
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Page 5 of 11Figure 4 Loss of Ran expression results in tumor regression in vivo. A. TOV112D TetR mixed population and clone expressing shRNA Ran
were subcutaneously injected in SCID mice and tumor growth was measured biweekly. All mice developed tumors albeit of varying size and
tumor volume. Doxycycline-supplemented food inducing shRNA expression started at day 9. M.P: Mixed population, Ran #2: clone. Values
represent mean ± SE of groups of 4 mice. Mann-Whitney test indicates a significant p-value < 0.05 (*). B. Immunohistochemistry analysis of the
xenografts on day 6 of the doxycycline-supplemented food showing morphological hematoxylin eosin (HE) staining and Ran, cleaved caspase-3
and Ki67 expression. Slides were obtained from contiguous tissues.
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Page 6 of 11high-grade invasive EOC [6]. Ran has previously been
reported to be overexpressed by several other cancer
types, such as stomach, colon, pancreas, lung and kidney
cancer [11-13,20]. In this study we demonstrated, using
a shRNA approach, that Ran appears to be essential for
EOC cell survival and that knockdown of Ran expres-
sion results in the caspase-3 associated apoptosis of
tumor cells.
We demonstrate here that downregulation of Ran not
only affects cellular proliferation but also results in a
decrease in the total number of cells. This result is in
line with other studies showing that Ran depletion in
cancer cells, using shRNA or siRNA, is associated with
inhibition of cell growth and cell death [12,20].
Inhibition of Ran expression caused cells to undergo
apoptosis as measured by cleaved caspase-3 protein
levels and by FACS analysis. Ran plays several essential
functions in cell physiology and it is not clear which of
these functions might be responsible for these effects on
tumor cell survival. One of Ran’s GTPase-related func-
tions is to regulate translocation of RNA and proteins
through the nuclear pore complex, including AKT, p53,
PTEN, NFB and cyclins [7,9,21]. Ran also functions,
independent of its role in nuclear pore transport, as a
signaling molecule regulating microtubule polymeriza-
tion during mitosis, deregulation of which may block
cell cycle progression and lead to cell death. We thus
analyzed the effect of Ran knockdown on cell cycle pro-
gression. As is generally observed in high grade serous
cancers, both the TOV112D and TOV1946 cell lines
harbor p53 mutations which correspond to those identi-
fied in the original tumor tissue [14,15]. Although one
could speculate that this lesion may influence the
response to loss of Ran expression, this seems unlikely
since it has previously been shown that the effects of
Ran loss on cell viability and hypodiploid DNA content
are indistinguishable whether wild-type or isogenic cells
deficient in p53 are used [12]. We did not observe cell
cycle arrest in our clones in any phase of the cell cycle.
However, a recent study demonstrated that downregula-
tion of Ran in human colon cancer cells provoked
S-phase arrest in K-Ras mutated cell lines, but not in
cells expressing wild-type K-Ras [22]. We had previously
checked for wild-type K-Ras in our cell lines and found
no known genetic alterations [14]. However, propidium
iodide analysis showed an increase in the sub-G1 phase
in our cells treated with shRNA Ran, indicating possible
presence of apoptotic cells following Ran depletion, that
was not reported in the study of Morgan-Lappe et al.
[22] on colon cancer cells. This may be explained by the
fact that they tested the cell cycle of their cells after 48
h of Ran depletion. At that time point, there was only a
slight difference in the sub-G1 cells proportion for
TOV112D TetR, while there was no difference in
TOV1946 TetR. Nevertheless, the induction of apoptosis
in colon cancer cells was observed by a caspase-3 activa-
tion assay after 72 h, demonstrating that Ran downregu-
lation leads to a caspase-3 associated apoptosis in both
models. The fast induction of apoptosis and the extent
of the response of the ovarian cancer cells to Ran deple-
tion suggest a particular sensitivity of ovarian cancer
cells to the loss of Ran.
As Ran depletion showed a dramatic effect on prolif-
eration in vitro, we were interested in the effect of its
downregulation in vivo. All TOV112D TetR cell lines
formed tumors when injected sub-cutaneously into
SCID mice, indicating that the repressor did not impair
the capacity of these cells to grow as xenografts in a
murine model. When induced, shRNA targeting Ran
resulted in a clear delay in tumor outgrowth and was
associated with induction of apoptosis within the tumor
cells, as observed by a cleaved caspase-3 IHC in the
xenografts. Interestingly, this delay was more evident in
clones which had the highest level of Ran suppression.
These results are in line with a study where siRNA was
used to downregulate Ran in a murine neuroblastoma
model [23]. This group showed that Ran depletion in
mice resulted in reduced tumor growth and was also
associated with induction of apoptosis.
It is likely that, in vivo, selective pressure results in the
outgrowth of cells able to escape Ran depletion. The
initial decrease in Ran expression following induction,
compared to its high expression in the eventual tumors
that formed, support this notion. In the shRNA Ran
mixed population, cells expressing less or no shRNA
against Ran would have a selective growth advantage
and could thus give rise to the eventual tumor. A similar
selection probably also occurs in the shRNA Ran clone
#3, although this epigenetic based effect results in
tumors taking longer to appear. In line with this hypoth-
esis, the immunohistochemistry of tumors six days after
induction showed only a slight decrease in Ran expres-
sion in the mixed population in contrast to stronger but
not complete inhibition seen in tumors derived from the
clonal population. Moreover, immunohistochemistry of
all tumors at the day of sacrifice showed that Ran
expression was similar to the controls, indicating that
Ran repression was lost.
Tumors with reduced expression of Ran showed
impaired nuclear Ki67 localization. Membranous and
cytoplasmic staining of Ki67 has already been described
in hyalinizing trabecular adenoma of the thyroid gland,
sclerosing haemangioma of the lung, pleomorphic ade-
noma of the salivary gland and invasive breast carcinoma
[24-27]. However, the mechanism of Ki67 localization
remains unknown. Given the role of Ran in nucleocyto-
plasmic transport, it is possible that this protein plays a
role in the transport of Ki67.
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involved in the host innate immune response against
microbial pathogens [28]. More recently, a study
revealed that transgenic mice overexpressing Ran have
reduced nuclear accumulation of c-Jun and c-Fos (AP-1
factors) in T cells, leading to diminished cytokine secre-
tion, decreased proliferation, and impaired in vivo Tc e l l
function [29]. It has also been reported that Ran overex-
pression in human glioblastoma cells increases their
resistance to paclitaxel treatment. In these cells, Ran can
inhibit Bcl-2 phosphorylation and thereby suppress
paclitaxel-induced apoptosis [30]. In EOC, standard
treatment is carboplatine/paclitaxel [31]. Unfortunately,
only 60-80% of women treated with these drugs respond
to first-line treatment and the majority will relapse [32].
Here, we show that Ran depletion has a major impact
on apoptosis of EOC cells, suggesting that Ran could be
a key player in the resistance of EOC cells to che-
motherapy by avoiding paclitaxel-induced apoptosis.
Ran depletion seems to affect cell viability in a variety
of cancer cells. In fact, inhibition of Ran expression in
ovarian, colon, breast, renal and nasopharyngeal tumor
cells leads to growth inhibition and/or cell death
[12,13,20,22]. In 2008, the group of Xia and al [12],
showed that Ran inhibition with siRNA for 72 h induces
aberrant mitotic formation, mitochondrial dysfunctions
and apoptosis of tumor cells. However, depletion of Ran
expression in normal fibroblasts was well tolerated, and
did not induce mitotic defects or loss of cell viability.
Conclusion
In conclusion, we demonstrate in this study that Ran
GTPase is essential for EOC cell survival in vitro and
in vivo. Ran downregulation triggers caspase-3 asso-
ciated apoptosis and causes a delay in tumor outgrowth.
Furthermore, tumor outgrowth is associated with the
selection of tumor cells which have escaped Ran deple-
tion. These results suggest that Ran could potentially be
a suitable therapeutic target for the treatment of ovarian
cancer.
Methods
Cell culture and generation of cell lines expressing the
tetracycline repressor
Two cell lines derived from aggressive EOC tumors
were used to downregulate the expression of Ran. Both
the TOV112D and TOV1946 ovarian cancer cell lines
have been described [14,15] and are known to express
high levels of Ran. Cells were grown as previously
described, in OSE complete medium (Wisent, Montreal,
Qc) containing 10% FBS, 2.5 μg/mL amphotericin B and
50 μg/mL gentamicin (Gibco, Grand Island, NY), at
37°C and 5% CO2 [14,15]. We generated stable cell lines
clones expressing the tetracycline repressor (TetR) by
transfection of the pcDNA6/TR vector (Invitrogen, cat.
No. V1025-20, Carlsbad, CA) with Lipofectamine (Invi-
trogen, Carlsbad, CA). TOV112D TetR and TOV1946
TetR cell lines clones were grown in OSE complete
medium supplemented with blasticidin. The tetracycline
repressor was required to prevent basal target gene
knockdown.
shRNA vector construction targeting RAN expression
To knockdown the expression of Ran, we used the
BLOCK-IT™ kit from Invitrogen. An oligonucleotide
encoding a stem-loop structure targeting Ran was
cloned in the pENTR/H1/T0 vector to generate an entry
vector. The sequence of the oligonucleotide (5’-cacca-
gaagaatcttcagtactattcgaaaatagtactgaagattcttc-3’)w a s
derived from a siRNA oligonucleotide previously shown
to target Ran [22]. As a non-specific control, an shRNA
targeting LacZ with the sequence: 5’-caccaaatcgct-
gatttgtgtagtcggagacgactacacaaatcagcga-3’ was used.
Using the Gateway® Cloning technology (Invitrogen,
Carlsbad, CA), an LR recombination (between attL and
attR sites) between the entry vector and the pLenti X1
Puro DEST destination vector (694-6; Addgene #17297)
[33] was performed to obtain the final expression vector.
Lentiviral production and transduction
The lentiviruses were produced by co-transfecting the
pLenti X1 Puro DEST-shRNA vector and the ViraPower
Lentiviral Packaging Mix (Invitrogen, Carlsbad, CA) in
the 293FT packaging cell line. The supernatant was col-
lected and concentrated by ultracentrifugation. For
infection, 2 × 10
5 cells per well were plated in 6-well
plates in 2 ml of growth culture medium one day before
infection to obtain 50-70% confluence. Infections were
performed in the presence of 5 μg/ml polybrene®
(Sigma, St. Louis, MO). Media was changed 16 h after
the infection and puromycin selection was performed
after two days.
Preparation of RNA and Reverse transcription-PCR
Total RNA was extracted from cells grown to 80% con-
fluence in 100 mm Petri dishes using TRIzol™ reagent
(Gibco/BRL, Life Technologies Inc., Grand Island, NY).
Cells expressing shRNA were induced three days before
RNA extraction with 1 μg/ml tetracycline. The quality
of RNA was tested with the RNA 6000 nano LabChip
kit using a 2100 bioanalyser (Agilent Technologies, Mis-
sissauga, ON). All RNA samples had RIN (RNA integrity
number) scores of at least eight.
Synthesis of cDNA was done using the QuantiTect
Reverse Transcription Kit for RT-PCR (Reverse tran-
scription polymerase chain reaction) (QIAGEN Inc.,
Mississauga, ON) according to the manufacturer’sp r o -
tocol, using 1 μgo ft o t a lR N Aa n d1μLo fR Tp r i m e r
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diluted 1:50 in water for the Q-PCR (Quantitative real-
time polymerase chain reaction) reaction. Q-PCR was
performed using the Rotor-gene 3000 Real-Time Centri-
fugal DNA Amplification System (Corbett Research,
Montreal Biotech Inc., Montreal, Qc). 5 μLo ft h es a m -
ple cDNA was mixed with 1 μL of the primers (10 μM)
and 12.5 μlQ u a n t i t e c h ™ SYBR Green PCR (QIAGEN
Inc., Mississauga, ON) for a final volume of 25 μl Nega-
tive controls were done in all experiments and ERK-1
served as the control. Two independent experiments
were each done in duplicate. Primer sequences were:
Ran 5’-agccccaggtccagttcaaac-3’ and 5’atggcacactgggcttg-
gata-3’,a n dE R K - 15 ’-gcgctggctcacccctacct-3’ and
5’-gccccagggtgcagagatgtc-3’.T om e a s u r et h er e l a t i v e
quantity of gene expression, the Pfaffl analysis method
was used [34].
Antibodies
The following antibodies were used for western blotting
and immunohistochemistry analysis: anti-Ran goat poly-
clonal (sc-1156, Santa Cruz Biotechnology, Santa Cruz,
CA), anti-cleaved Caspase-3 (Asp175) rabbit polyclonal
(#9661, Cell signaling Technologies, Beverly, MA), anti-
Ki67 rabbit polyclonal (RM 9106, NeoMarkers, Mon-
treal, Qc) and anti-ß-actin mouse monoclonal (AC15,
Abcam, Cambridge, MA).
Western blot analysis
Equal amounts of total protein extracts were loaded and
electrophoresed on SDS-polyacrylamide gels and trans-
ferred onto a nitrocellulose or PVDF membrane. The
membranes were blocked with 5% milk and probed with
primary antibodies. Dilutions used were 1:500 for Ran
and 1:250 for cleaved caspase-3. Each primary antibody
was detected with a conjugated secondary antibody-HRP
and visualized by the enhanced chemiluminescence
(ECL) method. Loading control for the samples was
confirmed by reprobing membranes with anti-actin.
Cellular growth
Cells were induced with 1 μg/ml tetracycline three days
prior to plating cells (day 0). On day 0, 2 × 10
5 cells were
seeded onto 6-well plates. Cells were trypsinized, resus-
pended in media and counted using a hemacytometer
every 24 h for the five following days. Each experiment
was performed in duplicate and was repeated three times.
Mitochondrial membrane potential (ΔΨm)
ΔΨm was measured by loading cells with tetramethylr-
hodamine ethylester (TMRE), a cell permeable, cationic,
nontoxic fluorescent dye that specifically stains live
mitochondria. TMRE is accumulated by the mitochon-
dria in proportion to membrane potential [35]. Briefly,
cells induced with 1 μg/ml tetracycline for different
times were incubated with 1.25 μMT M R E( c a t .n o
87917, Fluka, St. Louis, MO) for 20 minutes at 37°C.
Trypsinized cells were then collected with the superna-
tant, washed four times with phosphate buffered saline
(PBS), resuspended in 500 μlo fP B Sa n da n a l y z e dw i t h
the FL2 channel of a Coulter EPICS XL-MLC Flow
Cytometer.
Nuclear apoptosis detection
Frequency of hypodiploid cells (sub-G1) was quantified
by flow cytometry after staining the cells with propi-
dium iodide (PI). Briefly, cells induced with 1 μg/ml tet-
racycline for different times were collected with the
supernatant, washed and fixed with 70% cold ethanol
for 1 h at 4°C and stored at -20°C until staining was
performed. Cells were incubated 30 minutes at room
temperature with 500 μl of PBS containing 250 μgo f
RNase A (Roche, Mississauga, ON). 50 μg/ml of PI
(P-4864, Sigma-Aldrich, S t .L o u i s ,M O )w a sa d d e da n d
incubated for 10 more minutes at room temperature.
Cells were analyzed with the FL3 channel of a Coulter
EPICS XL-MLC Flow Cytometer.
Mice and tumor formation
Six weeks old female SCID CB17 mice (Charles River,
Montreal, QC) were injected with 1 × 10
6 cells sus-
pended in a mix of 1:1 PBS and matrigel (BD Bios-
ciences, Mississauga, ON) at subcutaneous sites.
Doxycycline-supplemented food (625 mg/kg) (Harlan,
Indianapolis, IN) was given at day 9 in experimental
groups and control groups continued to receive normal
food. One tumor from each group of seven mice was
collected and fixed in formalin on day 0, 3 and 6 of the
doxycycline-supplemented food and two tumors per
group of mice were collected at the moment of the
sacrifice. Data on weight of the mice and dimensions of
the tumors were collected twice a week. Animals were
housed under sterile conditions during all experimenta-
tions and were sacrificed before neoplastic masses
reached limit points establishes by the Institutional
Committee on Animal Protection (ICAP) according to
the Canadian Council on Animal Care.
Immunohistochemistry analysis
Tumors collected from mice were embedded in paraffin
after two days of formalin fixation at 4°C. A tissue
microarray (TMA) was constructed from the xenograft
blocks. Two punches of 0.6 mm diameter were taken
from each tumor. The TMA was cut with a 4 μmt h i c k -
ness, sectioned onto glass slides, and stained by an
immunoperoxidase method. Briefly, TMA slides were
heated at 60°C for 20 minutes, deparaffinized in xylene
and rehydrated in an ethanol gradient. Slides were then
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pressure (Cuisinart Pressure Cooker) for 15 minutes to
unmask antigens. Following a 3% H2O2 treatment to
eliminate endogenous peroxidase activity, slides were
blocked with a protein blocking reagent (DakoCytoma-
tion Inc., Mississauga, ON) for 15 minutes at room tem-
perature. Sections were incubated with primary
antibodies for 60 minutes at room temperature. Tissues
were incubated with secondary antibodies conjugated
with horseradish peroxidase (HRP) (Santa-Cruz, Santa
Cruz, CA) for 20 minutes at room temperature. Reac-
tion products were developed using diaminobenzidine
(Sigma-Aldrich, St. Louis, MO) containing 0.015%
H2O2. Nuclei were counterstained with hematoxylin.
Substitution of the primary antibody with PBS served as
a negative control. In wild-type TOV112D cells staining
for Ran is mainly cytoplasmic, whereas Ki67 and cleaved
caspase-3 are exclusively nuclear.
Statistical analysis
For statistical analysis, Mann-Whitney U-tests were car-
ried out using SPSS software (version 16.0). A P-value <
0.05 was considered statistically significant.
Additional material
Additional file 1: Effect of Ran depletion on proliferation. Growth
curves for TOV112D TetR (a) and TOV1946 TetR (b) parental cell lines,
mixed populations and clones expressing shRNA Ran or LacZ. Cells were
induced with tetracycline three days prior to day 0. Cells were
trypsinized and counted every 24 h for five days. Values represent the
mean ± SD of duplicate wells from three independent experiments.
Mann-Whitney test indicates no significant difference relative to the non-
induced parental cell line with p-value < 0.05.
Additional file 2: Tumor growth of mice injected with TOV112D
TetR shRNA LacZ. TOV112D TetR mixed population and clone
expressing shRNA LacZ were subcutaneously injected in SCID mice and
tumor growth was measured biweekly. All mice developed tumors albeit
of varying size and tumor volume. Doxycycline-supplemented food
inducing shRNA expression started at day 9. M.P.: Mixed population, #1:
clone. Values represent the mean ± SE of groups of 4 mice. Mann-
Whitney test indicates no significant difference relative to the group of
mice that did not received doxycycline, with a p-value < 0.05.
Additional file 3: Immunohistochemistry analysis of the xenografts
in control tumors. Analysis of the xenografts on day 6 of the
doxycycline-supplemented food showing morphological hematoxylin
eosin (HE) staining and Ran, cleaved caspase-3, and Ki67 expression.
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